EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market is segmented By Drug Type ( Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies), By Treatment Type (Monotherapy, Combination Therapy), By Stage of Disease (Locally Advanced NSCLC, Metastatic NSCLC), By Mutation Type (Exon 19 deletions, Exon 21 (L858R) substitution mutations, Exon 20 insertion mutations, Others), By Form (Capsules, Tablets, Injection), By Route of Administration (Oral, Intravenous), By Age (Adult, Geriatric), By Gender (Male, Female), By End User (Hospitals, Specialty Oncology Centers, Research Institutes, Others (Academic Institutes, etc.)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned.(2025-2032)